Upcoming Webinar
Build, Buy, or Blend: How Life Sciences Commercial Teams Should Approach AI Platform Strategy
Explore how life sciences organizations evaluate whether to build AI solutions internally, buy specialized platforms, or adopt a hybrid approach. Learn how each strategy impacts speed to insight, scalability, and commercial outcomes.
April 9, 2026 | 1:00–1:30 PM ET | 30 minutes
Why You Should Attend
-
Understand the Build vs. Buy vs. Blend framework for evaluating AI platforms in life sciences insights and analytics
-
Identify common pitfalls that delay value realization, such as data readiness, integration complexity, and internal resource constraints
-
Learn how life sciences teams are accelerating time-to-insight using AI
-
Discover how to ensure AI initiatives drive real business decisions, not just dashboards
Who Should Attend
Senior leaders and decision-makers across the following key areas:
-
Customer Insights & Market Research
-
Commercial Analytics & Data Science
-
Commercial Operations / Business Excellence
-
Medical Affairs
-
Brand / Franchise Strategy
-
Digital & Omnichannel Strategy
-
Market Access
-
AI Strategy, Governance & Enablement
-
IT & Data Platform Leadership
What We’ll Cover
-
The Build vs. Buy vs. Blend models for implementing AI in life sciences organizations
-
Key trade-offs organizations should consider when selecting an AI approach
-
Common challenges slowing AI adoption across commercial teams
-
A practical decision framework to help evaluate and implement the right AI strategy